Immunovaccine Inc.

Immunovaccine Inc.

October 27, 2009 08:30 ET

Immunovaccine Inc. Appoints Communications Director

HALIFAX, NOVA SCOTIA--(Marketwire - Oct. 27, 2009) - Immunovaccine Inc. (TSX VENTURE:IMV), a vaccine development company, today announced the appointment of Jennifer Ayotte as director of communications.

"Immunovaccine has successfully gone public and the addition of Jennifer to our team of talented professionals brings a depth of communications expertise that will support our goal of expanding awareness of our company and our vaccine product development," said Dr. Randal Chase, president and CEO of Immunovaccine Inc.

"Immunovaccine is at the forefront of vaccine development and I'm excited to join such an impressive management team," said Jennifer Ayotte, director of communications at Immunovaccine Inc.

Jennifer Ayotte brings 15 years of experience in public relations, corporate communications and marketing, both in-house and with agencies. She will be responsible for leading the day-to-day strategic communications and media relations efforts, and providing support for ongoing investor relations.

With extensive agency experience, Jennifer has worked with high profile clients in the pharmaceutical industry. Most recently, Jennifer was the director of client services for Impact Communications where she helped clients manage their reputation and communicate more effectively with their stakeholders. Prior to that role, she led communications for the Heart and Stroke Foundation.

Immunovaccine Inc. (TSX VENTURE:IMV) is a vaccine development company focused on the commercialization of its novel vaccine technology and product candidates. The company continues to strengthen its vaccine pipeline through licensing and strategic partnerships to develop therapeutic cancer and infectious disease vaccines.

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future are forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information